B4-007

B4-007: sourced facts only. name: "This study aimed to assess the therapeutic potential and molecular mechanisms of B4-007, an agonist peptide with high binding affinity (Kd = 7.0 nM) to EphB4, a receptor tyrosine kinase implicated in cancer progression and angiogenesis, in preclinical models of high-grade serous ovarian cancer (HGSC)." [DOI:10.1158/1538-7445.am2025-5625]; target: "This study aimed to assess the therapeutic potential and molecular mechanisms of B4-007, an agonist peptide with high binding affinity (Kd = 7.0 nM) to EphB4, a receptor tyrosine kinase implicated in cancer progression and angiogenesis, in preclinical models of high-grade serous ovarian cancer (HGSC)." [DOI:10.1158/1538-7445.am2025-5625]; developer: "UT MD Anderson Cancer Center, Houston, TX." [DOI:10.1158/1538-7445.am2025-5625]; modality: "B4-007, an agonist peptide with high binding affinity (Kd = 7.0 nM) to EphB4, a receptor tyrosine kinase implicated in cancer progression and angiogenesis, in preclinical models of high-grade serous ovarian cancer (HGSC)." [DOI:10.1158/1538-7445.am2025-5625]; stage: "B4-007 demonstrated significant anti-tumor efficacy as a single agent without apparent toxicity in orthotopic HGSC models." [DOI:10.1158/1538-7445.am2025-5625]